Darunavir Y Cobicistat

Resumen

Alternativas con registro en Colombia

• Lamivudina Y Zidovudina
• Lamivudina Y Abacavir
• Tenofovir Disoproxil Y Emtricitabina
• Abacavir/zidovudina/lamivudina
• Efavirenz. Tenofovir Disoproxil Y Emtricitabina
• Emtricitabina. Tenofovir Disoproxil Y Rilpivirina
• Emtricitabina. Tenofovir Disoproxil. Elvitegravir Y Cobicistat
• Lopinavir Y Ritonavir
• Lamivudina. Tenofovir Disoproxil Y Efavirenz
• Lamidubina. Abacavir Y Dolutegravir
• Emtricitabina Y Tenofovir Alafenamida
• Elvitegravir. Cobicistat. Emticitabina. Tenofovir Alafenamida

Estudios clínicos principales

• A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Co
  Fase 3 · 2015 · 725 participantes · Janssen Sciences Ireland UC · NCT02431247
• Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Al
  Fase 3 · 2015 · 1.149 participantes · Janssen R&D Ireland · NCT02269917
• Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacav
  Fase 3 · 2015 · 578 participantes · Gilead Sciences · NCT02603107 · PubMed 29925490 · PubMed 31430369
• Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
  Fase 3 · 2015 · 567 participantes · Gilead Sciences · NCT02469246 · PubMed 29475804 · PubMed 30932951

Enfermedades relacionadas

• VIH

Fuentes

• Etiqueta FDA (DailyMed): PREZCOBIX
• EMA: Symtuza
• EMA: Rezolsta